logo

Biotech Stocks Facing FDA Decision In July 2020

Introduction
Introduction

Ever since the pandemic began, the FDA panel meetings have been postponed or canceled.

With virtual meetings replacing in-person meetings, the regulatory agency has been successfully hosting webinars and training sessions remotely. However, an advisory committee meeting is yet to be held virtually, and for the first time, one such meeting has been scheduled for July.

As of this writing, 24 novel drugs have received FDA approval so far this year compared to just 13 during the same period last year. For the full year of 2019, forty-eight novel drugs made it to the finish line.

Let’s take a look at the biotech stocks facing FDA decision in July.

Share